|
|
|
« BACK
NEWS & PRESS RELEASE ARCHIVES
Wednesday, March 24, 2004 :: IMAGING DIAGNOSTIC SYSTEMS’ ANNUAL SHAREHOLDER MEETING Sunday, March 21, 2004 :: IMAGING DIAGNOSTIC SYSTEMS EXHIBITED AT THE EUROPEAN CONGRESS OF RADIOLOGY (ECR) Wednesday, February 25, 2004 :: IMAGING DIAGNOSTIC SYSTEMS IS AWARDED ITS SIXTEENTH U.S. PATENT Tuesday, February 24, 2004 :: IMAGING DIAGNOSTIC SYSTEMS INSTALLS ADDITIONAL CTLMâ SYSTEM FOR SCHERING AG’ STUDIES Tuesday, February 17, 2004 :: IMAGING DIAGNOSTIC SYSTEMS SHIPS FOUR SYSTEMS TO CHINA IN ACCORDANCE WITH A LETTER OF CREDIT PREVIOUSLY RECEIVED
IMAGING DIAGNOSTIC SYSTEMS’ ANNUAL SHAREHOLDER MEETING
HIGHLIGHTS PROGRESS, GROWTH and REPORTABLE REVENUES
FOR IMMEDIATE RELEASE
Ft. Lauderdale, Fl., March 25, 2004—Imaging Diagnostic Systems Inc. (IDSI) (OTC BB: IMDS) announced today that highlights of their annual shareholder meeting, which was held yesterday at 9:00 am at their corporate headquarters, included such announcements as reportable revenues from sales of the CT Laser Breast Imaging System (CTLM®), technological advancements, and future business strategies. The revenues of the sales will be reported in the Company’s next 10-Q filing.
Dr. Eric Milne, Chief Radiologist, of IDSI reported that the company received over 500 queries for the CTLM® at the recently attended European Congress of Radiology (ECR), and was nominated for “Best and Original Paper for Breast Imaging.” Milne also mentioned that the studies underway using their CTLM® system together with Schering’s AG fluorescent dyes have been very encouraging.”
In addition, Robert Wake, VP of Engineering of IDSI, made a presentation on the potential market of the company’s new Laser Imager for Laboratory Animals, (LILAÔ). Wake stated, “Optical Medical Imaging of laboratory animals to test pharmaceuticals is an excellent market to enter because each specially bred mouse can cost up to $30,000 and there are currently 30 million mice that are used each year for this type of research.”
According to Frost and Sullivan, a premier market and research firm, the animal scanning market is a new frontier with a market value of $100 Million and a projected annual growth in excess of 40%.
“If we can accelerate the typical 3½ year testing cycle of a drug before it can be tested on humans, we can save the pharmaceutical companies millions of dollars. We anticipate that together with our partner, Rumbaugh-Goodwin Institute for Cancer Research, we will be scanning mice before the end of this year for this purpose,” Wake added.
The meeting was brought to a close by Deborah O’Brien, Senior Vice President of IDSI, who recited a summation of some of the Company’s milestones this year, which included, but were not limited to:
· Canadian Market Approval
· Sale of three CTLM® systems in China
· Request of another CTLM® by Schering AG
· Deposit received on a Purchase Order in Argentina
· Nomination for Best and Original Paper on Breast Imaging at ECR
· Collaborative Agreement with Rumbaugh-Goodwin Institute of Cancer Research
Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast imaging system. The CTLM(R) system is the first patented breast-imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM(R) system to be used as an adjunct to mammography. The CTLM(R) system is a non-invasive, painless examination that does not expose the patient to radiation nor require breast compression.
Please visit Imaging Diagnostic Systems' website at: www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filing with the Securities Exchange Commission.
Investor Relations:
Rick Lutz
Lcgroup@mindspring.com
404-261-1196
Media Relations:
Margie Adelman
madelman@adelmancommunications.com
561-347-6768
IMAGING DIAGNOSTIC SYSTEMS EXHIBITED AT THE EUROPEAN CONGRESS OF RADIOLOGY (ECR)
Scientific Paper nominated for “Best and Original Paper of Breast Imaging"
FOR IMMEDIATE RELEASE
Ft. Lauderdale, Florida, March 22, 2004—Imaging Diagnostic Systems, Inc., (OTC BB:IMDS) announced today that the Company exhibited the CTLMâ systems’ clinical data at the European Congress of Radiology (ECR) conference, held March 5-9, 2004 in Vienna, Austria.
A scientific paper from the University of Vienna, (authors D. Floery, C. Riedl, W. Matzek, S. Jaromi, M.H. Fuchsjaeger and T. Helbich, M.D.), was presented at the ECR describing the typical vascular appearances of breast cancers imaged by the Company’s CTLMâ system. The authors studied the blood supply of 68 cancers, 59 of which were invasive and 9 non-invasive, or 'in situ,' (usually called a pre-malignant condition). 87% of the invasive cancers demonstrated vascular abnormalities on the CTLMâ image. 72% of these vascular abnormalities were due to new blood vessel growth (angiogenesis), and 28% to changes in the normal vessels of the breast. In contrast only 75% of the in situ lesions showed vascular changes. Of these only 57% were due to angiogenesis and 43% to changes in the normal vessels. None of the changes described could be identified on conventional X-ray mammography. Therefore the CTLMâ system adds a whole dimension of new knowledge to breast imaging. This presentation was nominated for the best and most original paper on breast imaging by the ECR conference.
The ECR attracts radiologists and scientists, not only from Europe but from around the world, who attend the congress in order to be informed about the latest scientific and professional advances in all fields of diagnostic imaging and interventional radiology. The ECR also showcases the largest commercial technical exhibition in Europe. As a result of the show the Company received numerous leads for potential sales and requests to represent the CTLMâ systems in many countries throughout the world.
Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast imaging system. The CTLMâ system is the first patented breast-imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross- sectional images of the breast. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography. The CTLMâ system is a non-invasive, painless examination that does not expose the patient to radiation nor require breast compression.
Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.
Investor Relations: Media Relations:
Rick Lutz Margie Adelman
Lcgroup@mindspring.com madelman@adelmancommunications.com
IMAGING DIAGNOSTIC SYSTEMS IS AWARDED ITS SIXTEENTH U.S. PATENT
FOR IMMEDIATE RELEASE
Fort Lauderdale, Florida, February 26, 2004—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced today that the U.S. Patent application filed October 2001, titled: “LASER IMAGING APPARATUS USING BIOMEDICAL MARKERS THAT BIND TO CANCER CELLS”, was granted to Robert Wake/IDSI VP of Engineering by the United States Patent and Trademark Office and assigned to Imaging Diagnostic Systems as U.S. Patent No. 6,693,287.
This patent protects the proprietary method of collecting data while using “biomedical” markers that bind to cancer cells during a CT laser scan to provide a positive identification of the cancer area, to selectively activate the Photo Dynamic Therapy (PDT) drug to destroy the cancer. This is a combined diagnostic and therapeutic system.
In addition to the 16 U.S. patents, there are 35 international patents pending which protect the proprietary technology of the CT Laser breast imaging system globally. The software that operates the CTLMâ system is encrypted uniquely on each system, protecting the intellectual property embodied in that software.
Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast imaging system. The CTLMâ system is the first patented breast-imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross- sectional images of the breast. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography. The CTLMâ system is a non-invasive, painless examination that does not expose the patient to radiation nor require breast compression.
Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.
Investor Relations: Media Relations:
Rick Lutz Margie Adelman
lcgroup@mindspring madelman@adelmancommunications.com
404-261-1196 561.347.6768
IMAGING DIAGNOSTIC SYSTEMS INSTALLS ADDITIONAL CTLMâ SYSTEM FOR SCHERING AG’ STUDIES
FOR IMMEDIATE RELEASE
Fort Lauderdale, Florida, February 25, 2004—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced today that Schering AG, Germany, has requested an additional CTLMâ system as part of their collaborative efforts with IDSI to continue their studies of fluorescent compounds in their quest of breast cancer detection.
Schering AG and Imaging Diagnostic Systems previously signed a collaborative agreement designed to evaluate the advantages of new fluorescence dyes developed by Schering AG, for the potential use of detecting breast cancer. Imaging Diagnostics’ CTLM® system will be used in conjunction with Schering AG’s dyes during Schering’s clinical trials. The collaboration will assist in determining the potential benefits of using both technologies adjunctively to further enhance the CTLM® systems capabilities in detecting breast cancer.
Schering AG is a research-based pharmaceutical company. Its activities are focused on four business areas: Gynecology&Andrology, Diagnostics & Radiopharmaceuticals, Dermatology as well as Specialized Therapeutics for disabling diseases in the fields of the central nervous system, oncology and cardiovascular system. As a global player with innovative products Schering AG aims for leading positions in specialized markets worldwide. With in-house R&D and supported by an excellent global network of external partners, Schering AG is securing a promising product pipeline. Using new ideas, Schering AG aims to make a recognized contribution to medical progress and strives to improve the quality of life.
Imaging Diagnostic Systems has received CE Marking, UL listing, ISO 9001:2000 certification and FDA export certification for its CT Laser Breast imaging system. The CTLMâ system is the first patented breast-imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross- sectional images of the breast. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography. The CTLMâ system is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression.
Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.
Investor Relations: Public Relations:
Rick Lutz Margie Adelman
404-261-1196 madelman@adelmancommunications.com
Lcgroup@mindspring.com 561.347.6768
IMAGING DIAGNOSTIC SYSTEMS SHIPS FOUR SYSTEMS TO CHINA IN ACCORDANCE WITH A LETTER OF CREDIT PREVIOUSLY RECEIVED
FOR IMMEDIATE RELEASE
Fort Lauderdale, Florida, February 18, 2004—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced today that the Company shipped four CTLMâ systems to China in accordance with an irrevocable confirmed letter of credit. As we previously reported, an order was placed for three CTLMâ systems by China Far East International Trade Corporation, Shenzhen, China. The fourth system will be used for clinical research by the Government of China.
Established in 1985 with the approval of the Ministry of Foreign Trade and Economic Cooperation, China Far East International Trade Corporation (CFETC) has become one of China’s top 500 enterprises with the largest import and export volume. CFETC is headquartered in located in Beijing and has numerous satellite offices throughout China.
China has over 330,000 medical institutions, both Chinese and foreign funded, with a population of approximately 1.3 billion people. The Chinese market for medical equipment is currently ranked the eleventh largest medical device market. The potential size of China’s medical device market is vast and most experts agree that at some point, China will be the largest single country market for U.S. medical device exporters. The U.S. is the leading supplier of imported medical devices, accounting for one third of all medical device imports.
Imaging Diagnostic Systems has received CE Marking, UL listing, ISO 9001:2000 certification and FDA export certification for its CT Laser Breast imaging system. The CTLMâ system is the first patented breast-imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross- sectional images of the breast. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLMâ system to be used as an adjunct to mammography. The CTLMâ system is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression.
Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.
Investor Relations: Public Relations:
Rick Lutz Margie Adelman
404-261-1196 madelman@adelmancommunications.com
Lcgroup@mindspring.com 561.347.6768
